This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
With the FDA recently clearing BrainsWay Deep TMS treatment for OCD, the mental health community is excited, generating significant interest in offering BrainsWay therapy. Physicians have been discussing OCD treatment options beyond medications for over a decade, and now Deep TMS offers that solution.